Redefining Adnexal Mass Management with Precise Care
Complementing your adnexal mass protocol, OvaWatch® and Ova1Plus® offer an individualized approach to risk assessment, to help ensure the right patient receives the right treatment at the right time.
Our OvaSuiteSM Portfolio of Products
Our non-invasive blood tests offers precise tools to inform ovarian care, helping providers enhance confidence in their medical management plans and triage specialist referrals more efficiently.
Planned for Clinical Management
- For adnexal masses initially evaluated as indeterminate or benign
- Negative Predictive Value of over 99%1
- Longitudinal monitoring feature to help providers track risk over time
Planned for Surgical Management
- For adnexal masses that are planned for surgery
- Ova1® has a sensitivity of over 96% with clinical assessment2
- Biomarkers (including CA-125), menopausal status, and ultrasound for a personalized risk score
Ova1Plus is a reflex process: Ova1® is performed first. If an intermediate risk is detected, Overa® is automatically performed.
Watch This Video to Learn Which Test Is Best for Your Patient
How It Works
BEFORE THE TEST
Single blood draw, performed in healthcare provider's office or partner laboratories
DURING THE TEST
Proprietary algorithms incorporate patient features and levels of up to 7 biomarkers
AFTER THE TEST
Results include risk score, ovarian cancer risk assessment, and CA-125 result
Our Services
Price Transparency & Financial Assistance to Patients
We are committed to making tests available to all women who need them. Covered by Medicare, Medicaid, and commercial insurance in many states. Cash pay is $295 per test. Financial assistance and payment plans are available for qualifying patients.
PRECAUTION:
OVAWATCH IS INTENDED FOR USE AS A NON-INVASIVE TEST TO ASSESS THE RISK OF OVARIAN CANCER FOR WOMEN WITH ADNEXAL MASSES, EVALUATED BY INITIAL CLINICAL ASSESSMENT (ICA) AS INDETERMINATE OR BENIGN. IN CONJUNCTION WITH IMAGING (ULTRASOUND AND/OR CT) AND CLINICAL ASSESSMENT, THIS TEST WILL SUPPORT PHYSICIANS IN MAKING INFORMED CLINICAL DECISIONS IN THE MANAGEMENT OF WOMEN WITH ADNEXAL MASSES. THE TEST IS NOT INTENDED AS A SCREENING TEST OR A STAND-ALONE DIAGNOSTIC ASSAY.
OVA1 AND OVERA SHOULD NOT BE USED WITHOUT AN INDEPENDENT CLINICAL AND IMAGING EVALUATION AND IS NOT INTENDED TO BE A SCREENING TEST OR TO DETERMINE WHETHER A PATIENT SHOULD PROCEED TO SURGERY. INCORRECT USE CARRIES THE RISK OF UNNECESSARY TESTING, SURGERY, AND/OR DELAYED DIAGNOSIS.